Clinical and preclinical studies demonstrate GLP‐1 RAs as excellent weight loss drugs with therapeutic potential for obesity‐related illness, emphasizing the need for rigorous investigation to ensure safe clinical use in breast oncology. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.